The regulatory path for nasal sprays is complex because they are considered "Combination Products" (Drug + Device). For generic versions, manufacturers must prove "Bioequivalence" not only through blood plasma levels but also through "In Vitro" testing that compares the spray's physical characteristics to the Reference Listed Drug (RLD). This includes rigorous testing of the pump’s...